MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

16.26 2.2

Resumen

Variación precio

24h

Actual

Mínimo

15.89

Máximo

16.35

Métricas clave

By Trading Economics

Ingresos

222M

227M

Ventas

-23M

139M

P/B

Media del Sector

6.117

35.739

Margen de beneficios

163.843

Empleados

1,780

EBITDA

6.3M

1.3M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+16.27% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

76M

2.8B

Apertura anterior

14.06

Cierre anterior

16.26

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

183 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2025, 16:58 UTC

Ganancias

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct 2025, 23:19 UTC

Charlas de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct 2025, 22:40 UTC

Charlas de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 20:44 UTC

Acciones populares

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct 2025, 19:42 UTC

Charlas de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct 2025, 19:23 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct 2025, 15:33 UTC

Charlas de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct 2025, 15:25 UTC

Charlas de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct 2025, 15:15 UTC

Charlas de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct 2025, 15:04 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 oct 2025, 15:04 UTC

Charlas de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct 2025, 14:52 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

16.27% repunte

Estimación a 12 Meses

Media 18.58 USD  16.27%

Máximo 25 USD

Mínimo 13.75 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

1

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

183 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat